Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tu
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Movi
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi